Double-Drug attack shows promise against advanced skin cancer
NCT ID NCT04889118
First seen Dec 31, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that cannot be removed by surgery. The trial included 131 Chinese participants who had not received prior treatment for their advanced disease. Researchers measured how long participants lived without their cancer worsening and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital (0601)
Beijing, Beijing Municipality, 100036, China
-
Fudan University Shanghai Cancer Center ( Site 0607)
Shanghai, Shanghai Municipality, 200032, China
-
Fujian Provincial Cancer Hospital ( Site 0612)
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital ( Site 0610)
Zhengzhou, Henan, 450003, China
-
Nanjing Drum Tower Hospital (0609)
Nanjing, Jiangsu, 210008, China
-
Sir Run Run Shaw Hospital (0605)
Hangzhou, Zhejiang, 310018, China
-
Sun Yat-Sen University Cancer Center (0602)
Guangzhou, Guangdong, 510000, China
-
The First Hospital Of Jilin University (0603)
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital (0606)
Tianjin, Tianjin Municipality, 300060, China
-
Yunnan Cancer Hospital (0604)
Kunming, Yunnan, 430030, China
-
Zhejiang Cancer Hospital ( Site 0608)
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.